Acasti Pharma Cmn A (ACST) 1.55 $ACST
Acasti Announces Grant of Stock Options
Marketwire Canada - Mon May 30, 7:01AM CDT
LAVAL, QUEBEC--(Marketwired - May 30, 2016) - Acasti Pharma Inc. ("Acasti" or the "Corporation"
(NASDAQ:ACST)(TSX VENTURE:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia, announces the grant of 310,400 stock options under its Stock Option Plan to its employees, including 200,000 to the Chairman of the Board and 61,400 to the officers. Each option will vest gradually over a period of 3 years (1/3 per year) and will allow its holder to acquire one class A common share of the Company at a price of $1.99 until May 29, 2023.
ACST: 1.55 (unch), APO.VN: 2.090 (-0.010)
Acasti Announces Fourth Quarter and Fiscal Year Results
Marketwire Canada - Wed May 25, 4:01PM CDT
LAVAL, QUEBEC--(Marketwired - May 25, 2016) - Acasti Pharma Inc. ("Acasti" or the "Corporation" (NASDAQ:ACST)(TSX VENTURE:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia, announces its operating and financial results for the fourth quarter and fiscal year ended February 29, 2016. All amounts are in Canadian dollars.
ACST: 1.55 (unch), NTB.TO: 1.43 (+0.02), NEPT: 1.08 (-0.01), APO.VN: 2.090 (-0.010)
Jan D'Alvise Appointed President & CEO of Acasti Pharma
Marketwire Canada - Thu May 12, 7:09AM CDT
Seasoned Executive in Drug Development
ACST: 1.55 (unch), NTB.TO: 1.43 (+0.02), NEPT: 1.08 (-0.01), APO.VN: 2.090 (-0.010)
Neptune Announces Preliminary Q4 Results
Marketwired - Tue Apr 05, 6:31AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company" (NASDAQ: NEPT)(TSX: NTB), announces preliminary selected results for the fourth quarter ended February 29, 2016. All amounts in Canadian dollars. The financial information in this press release excludes Acasti Pharma.
ACST: 1.55 (unch), NTB.TO: 1.43 (+0.02), NEPT: 1.08 (-0.01)
Nasdaq Grants Acasti Cure Period to Regain Compliance with Audit Committee Membership Requirements
Marketwired - Fri Mar 25, 1:03PM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation" (NASDAQ: ACST)(TSX VENTURE: APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of hypertriglyceridemia, announces that on March 22, 2016, it received a Nasdaq Deficiency Letter (the "Nasdaq Letter" confirming that the Corporation is no longer in compliance with Nasdaq Listing Rule 5605, requiring a company's audit committee to be comprised of at least three independent directors. Following the resignation of several board members on February 29, 2016, Acasti's Audit Committee is currently comprised of two independent directors.
ACST: 1.55 (unch), APO.VN: 2.090 (-0.010)
Acasti Announces Share-for-Debt
Marketwired - Fri Feb 05, 4:31PM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation" (NASDAQ: ACST)(TSX VENTURE: APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of hypertriglyceridemia, announces the issuance of fifty thousand class A common shares as part of a settlement agreement executed on February 5, 2016.
ACST: 1.55 (unch), APO.VN: 2.090 (-0.010)
Dyslipidemia Pipeline Review, H2 2015
M2 - Fri Feb 05, 6:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/bbj35n/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dyslipidemia Overview - Therapeutics Development - Pipeline Products for Dyslipidemia - Overview - Pipeline Products for Dyslipidemia - Comparative Analysis - Dyslipidemia - Therapeutics under Development by Companies - Dyslipidemia - Therapeutics under Investigation by Universities/Institutes - Dyslipidemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dyslipidemia - Products under Development by Companies - Dyslipidemia - Products under Investigation by Universities/Institutes - Dyslipidemia - Companies Involved in Therapeutics Development (Partial List) - Acasti Pharma Inc. - Allergan Plc - Alnylam Pharmaceuticals, Inc. - Amgen Inc. - Arbutus Biopharma Corporation - Arisaph Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AtheroNova Inc. - BASF SE - BCWorld Pharm Co. Ltd. - Cadila Pharmaceuticals Ltd. - Cardax Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - Cerenis Therapeutics Holding SA - Chong Kun Dang Pharmaceutical Corp. - CJ HealthCare Corp. - Connexios Life Sciences Pvt. Ltd. - CymaBay Therapeutics, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Gemphire Therapeutics Inc. - Genfit SA - GlaxoSmithKline Plc - HanAll Biopharma Co., Ltd. - Hanmi Pharmaceuticals, Co. Ltd. - Huons Co., Ltd. - Hyundai Pharmaceutical Co., Ltd. - Innovent Biologics, Inc. - IPCA Laboratories Limited - Isis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Jenrin Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/bb...slipidemia
AMGN: 174.16 (+2.13), LLY: 83.18 (+0.29), GSK: 45.25 (+0.18), AGN: 254.86 (+1.91), ABUS: 4.17 (+0.08), ACST: 1.55 (unch), ISIS: 57.56 (-0.28), AZN: 33.84 (-0.30), CBAY: 1.85 (-0.04)
Acasti incurs Q3 net loss of CAD2.191m
M2 - Wed Jan 13, 6:07AM CST
Biopharmaceutical company Acasti Pharma (NasdaqCM:ACST) stated on Tuesday that it recorded a net loss of CAD2.191m for the third quarter ended 30 November 2015.
ACST: 1.55 (unch)
Acasti reports 3Q loss
Automated Insights - Tue Jan 12, 5:24PM CST
LAVAL, Quebec (AP) _ Acasti Pharma Inc. (ACST) on Tuesday reported a fiscal third-quarter loss of $1.7 million, after reporting a profit in the same period a year earlier.
ACST: 1.55 (unch)
Acasti Announces Third Quarter Results
GlobeNewswire - Tue Jan 12, 4:26PM CST
-- Important progress made with FDA on CaPre(R) development pathway
ACST: 1.55 (unch), APO.VN: 2.090 (-0.010)
Acasti Provides Update on CaPre(R) Development Pathway
GlobeNewswire - Wed Dec 16, 6:50AM CST
-- Encouraging response from FDA on CaPre(R) clinical development
ACST: 1.55 (unch), APO.VN: 2.090 (-0.010)
Acasti Granted Composition & Use Patent in Japan, Taiwan and Mexico
GlobeNewswire - Tue Dec 01, 6:30AM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation" (NASDAQ:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that the Japanese, Taiwanese and Mexican patent offices have each recently granted Acasti a composition and use patent (the "Patents" .
ACST: 1.55 (unch), APO.VN: 2.090 (-0.010)
TSX Venture Exchange Daily Bulletins
CNW Group - Wed Oct 14, 5:14PM CDT
TSX VENTURE COMPANIES
ACST: 1.55 (unch)
Acasti Announces Grant of Stock Options
Marketwire Canada - Mon May 30, 7:01AM CDT
LAVAL, QUEBEC--(Marketwired - May 30, 2016) - Acasti Pharma Inc. ("Acasti" or the "Corporation"
(NASDAQ:ACST)(TSX VENTURE:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia, announces the grant of 310,400 stock options under its Stock Option Plan to its employees, including 200,000 to the Chairman of the Board and 61,400 to the officers. Each option will vest gradually over a period of 3 years (1/3 per year) and will allow its holder to acquire one class A common share of the Company at a price of $1.99 until May 29, 2023. ACST: 1.55 (unch), APO.VN: 2.090 (-0.010)
Acasti Announces Fourth Quarter and Fiscal Year Results
Marketwire Canada - Wed May 25, 4:01PM CDT
LAVAL, QUEBEC--(Marketwired - May 25, 2016) - Acasti Pharma Inc. ("Acasti" or the "Corporation"
(NASDAQ:ACST)(TSX VENTURE:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia, announces its operating and financial results for the fourth quarter and fiscal year ended February 29, 2016. All amounts are in Canadian dollars. ACST: 1.55 (unch), NTB.TO: 1.43 (+0.02), NEPT: 1.08 (-0.01), APO.VN: 2.090 (-0.010)
Jan D'Alvise Appointed President & CEO of Acasti Pharma
Marketwire Canada - Thu May 12, 7:09AM CDT
Seasoned Executive in Drug Development
ACST: 1.55 (unch), NTB.TO: 1.43 (+0.02), NEPT: 1.08 (-0.01), APO.VN: 2.090 (-0.010)
Neptune Announces Preliminary Q4 Results
Marketwired - Tue Apr 05, 6:31AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company"
(NASDAQ: NEPT)(TSX: NTB), announces preliminary selected results for the fourth quarter ended February 29, 2016. All amounts in Canadian dollars. The financial information in this press release excludes Acasti Pharma. ACST: 1.55 (unch), NTB.TO: 1.43 (+0.02), NEPT: 1.08 (-0.01)
Nasdaq Grants Acasti Cure Period to Regain Compliance with Audit Committee Membership Requirements
Marketwired - Fri Mar 25, 1:03PM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation"
(NASDAQ: ACST)(TSX VENTURE: APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of hypertriglyceridemia, announces that on March 22, 2016, it received a Nasdaq Deficiency Letter (the "Nasdaq Letter" confirming that the Corporation is no longer in compliance with Nasdaq Listing Rule 5605, requiring a company's audit committee to be comprised of at least three independent directors. Following the resignation of several board members on February 29, 2016, Acasti's Audit Committee is currently comprised of two independent directors. ACST: 1.55 (unch), APO.VN: 2.090 (-0.010)
Acasti Announces Share-for-Debt
Marketwired - Fri Feb 05, 4:31PM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation"
(NASDAQ: ACST)(TSX VENTURE: APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of hypertriglyceridemia, announces the issuance of fifty thousand class A common shares as part of a settlement agreement executed on February 5, 2016. ACST: 1.55 (unch), APO.VN: 2.090 (-0.010)
Dyslipidemia Pipeline Review, H2 2015
M2 - Fri Feb 05, 6:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/bbj35n/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dyslipidemia Overview - Therapeutics Development - Pipeline Products for Dyslipidemia - Overview - Pipeline Products for Dyslipidemia - Comparative Analysis - Dyslipidemia - Therapeutics under Development by Companies - Dyslipidemia - Therapeutics under Investigation by Universities/Institutes - Dyslipidemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dyslipidemia - Products under Development by Companies - Dyslipidemia - Products under Investigation by Universities/Institutes - Dyslipidemia - Companies Involved in Therapeutics Development (Partial List) - Acasti Pharma Inc. - Allergan Plc - Alnylam Pharmaceuticals, Inc. - Amgen Inc. - Arbutus Biopharma Corporation - Arisaph Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AtheroNova Inc. - BASF SE - BCWorld Pharm Co. Ltd. - Cadila Pharmaceuticals Ltd. - Cardax Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - Cerenis Therapeutics Holding SA - Chong Kun Dang Pharmaceutical Corp. - CJ HealthCare Corp. - Connexios Life Sciences Pvt. Ltd. - CymaBay Therapeutics, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Gemphire Therapeutics Inc. - Genfit SA - GlaxoSmithKline Plc - HanAll Biopharma Co., Ltd. - Hanmi Pharmaceuticals, Co. Ltd. - Huons Co., Ltd. - Hyundai Pharmaceutical Co., Ltd. - Innovent Biologics, Inc. - IPCA Laboratories Limited - Isis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Jenrin Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/bb...slipidemia
AMGN: 174.16 (+2.13), LLY: 83.18 (+0.29), GSK: 45.25 (+0.18), AGN: 254.86 (+1.91), ABUS: 4.17 (+0.08), ACST: 1.55 (unch), ISIS: 57.56 (-0.28), AZN: 33.84 (-0.30), CBAY: 1.85 (-0.04)
Acasti incurs Q3 net loss of CAD2.191m
M2 - Wed Jan 13, 6:07AM CST
Biopharmaceutical company Acasti Pharma (NasdaqCM:ACST) stated on Tuesday that it recorded a net loss of CAD2.191m for the third quarter ended 30 November 2015.
ACST: 1.55 (unch)
Acasti reports 3Q loss
Automated Insights - Tue Jan 12, 5:24PM CST
LAVAL, Quebec (AP) _ Acasti Pharma Inc. (ACST) on Tuesday reported a fiscal third-quarter loss of $1.7 million, after reporting a profit in the same period a year earlier.
ACST: 1.55 (unch)
Acasti Announces Third Quarter Results
GlobeNewswire - Tue Jan 12, 4:26PM CST
-- Important progress made with FDA on CaPre(R) development pathway
ACST: 1.55 (unch), APO.VN: 2.090 (-0.010)
Acasti Provides Update on CaPre(R) Development Pathway
GlobeNewswire - Wed Dec 16, 6:50AM CST
-- Encouraging response from FDA on CaPre(R) clinical development
ACST: 1.55 (unch), APO.VN: 2.090 (-0.010)
Acasti Granted Composition & Use Patent in Japan, Taiwan and Mexico
GlobeNewswire - Tue Dec 01, 6:30AM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation"
(NASDAQ:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that the Japanese, Taiwanese and Mexican patent offices have each recently granted Acasti a composition and use patent (the "Patents" . ACST: 1.55 (unch), APO.VN: 2.090 (-0.010)
TSX Venture Exchange Daily Bulletins
CNW Group - Wed Oct 14, 5:14PM CDT
TSX VENTURE COMPANIES
ACST: 1.55 (unch)
